Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Alzheon has raised $100.0M in total funding. The most recent round was Series E. The last funding was announced in June 2024.
Alzheon's investors include Ally Bridge Group, National Institute on Aging, Scott H. Cohen, Alerce Medical Technology Partners.
Alzheon is headquartered in Framingham, United States.
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Alzheon is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alzheon — Funding & Investors." VCBacked, June 12, 2024, https://www.vcbacked.co/company/alzheon. Accessed September 29, 2026.
VCBacked. (2024). Alzheon — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/alzheon
{{cite web |title=Alzheon — Funding & Investors |url=https://www.vcbacked.co/company/alzheon |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated